Amit I Bery1, Hrishikesh S Kulkarni1, Daniel Kreisel2. 1. Division of Pulmonary and Critical Care Medicine, Department of Medicine. 2. Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Abstract
PURPOSE OF REVIEW: The aim of this study was to provide a critical appraisal of the literature on the effects of the COVID-19 pandemic on organ transplantation, with a specific focus on lung transplantation given the predominant pulmonary involvement of the virus. RECENT FINDINGS: There was a significant decrease in lung transplant volumes during the first wave of the COVID-19 pandemic due to a combination of reduced availability of donors and an imbalance between waitlist additions and inactivations. SARS-CoV-2 infection was subsequently associated with an exuberant immune response that can lead to the development of postinfectious fibrotic lung disease. Few lung transplants have been performed in previously infected recipients and long-term outcomes remain unknown. Although the lung transplant volume rebounded during the second wave, it is unclear what the long-term effects of healthcare resource limitation and public health measures will have on transplant volumes in the future. Outcomes after SARS-CoV-2 infection in previous lung transplant recipients appear to be worse than the general public, and, although an immunosuppressed state likely contributes to these outcomes, whether immunosuppression should be altered in those exposed to or infected with SARS-CoV-2 remains unanswered in the absence of unequivocal data. SUMMARY: The COVID-19 pandemic has presented a number of challenges for lung transplant programs across the globe. Multiple research questions remain to be answered in order to optimally manage lung transplant recipients in the context of this pandemic.
PURPOSE OF REVIEW: The aim of this study was to provide a critical appraisal of the literature on the effects of the COVID-19 pandemic on organ transplantation, with a specific focus on lung transplantation given the predominant pulmonary involvement of the virus. RECENT FINDINGS: There was a significant decrease in lung transplant volumes during the first wave of the COVID-19 pandemic due to a combination of reduced availability of donors and an imbalance between waitlist additions and inactivations. SARS-CoV-2 infection was subsequently associated with an exuberant immune response that can lead to the development of postinfectious fibrotic lung disease. Few lung transplants have been performed in previously infected recipients and long-term outcomes remain unknown. Although the lung transplant volume rebounded during the second wave, it is unclear what the long-term effects of healthcare resource limitation and public health measures will have on transplant volumes in the future. Outcomes after SARS-CoV-2 infection in previous lung transplant recipients appear to be worse than the general public, and, although an immunosuppressed state likely contributes to these outcomes, whether immunosuppression should be altered in those exposed to or infected with SARS-CoV-2 remains unanswered in the absence of unequivocal data. SUMMARY: The COVID-19 pandemic has presented a number of challenges for lung transplant programs across the globe. Multiple research questions remain to be answered in order to optimally manage lung transplant recipients in the context of this pandemic.
Authors: Olivia S Kates; Cynthia E Fisher; Robert M Rakita; Jorge D Reyes; Ajit P Limaye Journal: Am J Transplant Date: 2020-06-18 Impact factor: 8.086
Authors: John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane Journal: N Engl J Med Date: 2020-10-08 Impact factor: 91.245
Authors: Leticia Kuri-Cervantes; M Betina Pampena; Wenzhao Meng; Aaron M Rosenfeld; Caroline A G Ittner; Ariel R Weisman; Roseline S Agyekum; Divij Mathew; Amy E Baxter; Laura A Vella; Oliva Kuthuru; Sokratis A Apostolidis; Luanne Bershaw; Jeanette Dougherty; Allison R Greenplate; Ajinkya Pattekar; Justin Kim; Nicholas Han; Sigrid Gouma; Madison E Weirick; Claudia P Arevalo; Marcus J Bolton; Eileen C Goodwin; Elizabeth M Anderson; Scott E Hensley; Tiffanie K Jones; Nilam S Mangalmurti; Eline T Luning Prak; E John Wherry; Nuala J Meyer; Michael R Betts Journal: Sci Immunol Date: 2020-07-15
Authors: Saima Aslam; Daniel R Goldstein; Robin Vos; Andrew E Gelman; Michelle M Kittleson; Cameron Wolfe; Lara Danziger-Isakov Journal: J Heart Lung Transplant Date: 2021-01-02 Impact factor: 10.247
Authors: Christian Lang; Peter Jaksch; Mir Alireza Hoda; György Lang; Thomas Staudinger; Edda Tschernko; Bernhard Zapletal; Silvana Geleff; Helmut Prosch; Riem Gawish; Sylvia Knapp; Oliver Robak; Florian Thalhammer; Alexander Indra; Markus Koestenberger; Robert Strassl; Thomas Klikovits; Kamran Ali; Gottfried Fischer; Walter Klepetko; Konrad Hoetzenecker; Peter Schellongowski Journal: Lancet Respir Med Date: 2020-08-25 Impact factor: 30.700
Authors: Victor C Passarelli; Klinger Faico-Filho; Luiz Vinicius Leão Moreira; Ana Paula Cunha; Joseane Mayara Almeida Carvalho; Gabriela Rodrigues Barbosa; Clarice Camargo; Danielle D Conte; Ana H Perosa; Nancy Bellei Journal: Int J Infect Dis Date: 2020-10-28 Impact factor: 3.623